Technology
Health
Biotechnology

Aquinox Pharmaceuticals

$2.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
+$0.02 (0.75%) After Hours

Why Robinhood?

You can buy or sell AQXP and other stocks, options, ETFs, and crypto commission-free!

About

Aquinox Pharmaceuticals, Inc. Common Stock, also called Aquinox Pharmaceuticals, is a clinical-stage pharmaceutical company. Read More It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

Employees
8
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
63.08M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
306.18K
High Today
$2.71
Low Today
$2.64
Open Price
$2.66
Volume
18.50K
52 Week High
$16.14
52 Week Low
$1.96

Collections

Technology
Health
Biotechnology
Medical
Pharmaceutical
Therapy
2014 IPO
Canada

News

Yahoo FinanceApr 26

What Kind Of Shareholder Appears On The Aquinox Pharmaceuticals, Inc.'s (NASDAQ:AQXP) Shareholder Register?

The big shareholder groups in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership. Aquinox Pharmaceuticals is a smaller company with a market capitalization of US$64m, so it may still be flying under the radar of many institutional investors. In the chart below below, we can see that institution...

88

Earnings

-$0.69
-$0.42
-$0.15
$0.12
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.05 per share
Actual
Expected May 29, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.